Loading stock data…
Cellectar Biosciences (CLRB)
$2.41+0.04 (+1.69%)
Market ClosedLast close Sep 8
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cellectar Biosciences, Inc. in the Healthcare sector is trading at $2.41 with a market capitalization of $18M. Wall Street consensus targets $11.50 (4 analysts), implying a +377.2% move over the next 12 months. The stock is currently near its 52-week low of $2.20, remaining 17.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +377.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 28) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.79M↓ | -$5.69M↓ | -$4.85M↑ | -$6.04M↑ | -$6.40M |
| Net Income | -$5.65M↓ | -$5.30M↓ | -$4.44M↑ | -$5.45M↑ | -$6.60M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-624.90%
Volume
Today's trading volume
27,167
Recent News
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
Phase 3 trial underway for iopofosine I 131 in Waldenstrom's macroglobulinemia.
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...
Company reports 79.2% major response rate in high-risk WM patients and secures up to $140 million to support NDA submission and pipeline expansion.
Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary
Moby summary of Cellectar Biosciences, Inc.'s Q2 2026 earnings call
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk
Cellectar Biosciences is back in focus after its fair value estimate was reset from US$76.00 to about US$10.33, a sharp shift that lines up more closely with the latest US$10 analyst price target. Recent research commentary links this change to a mix of optimism around that US$10 target and caution about how the company delivers against the assumptions behind it. As you read on, you will see how this evolving price target story shapes the broader narrative around Cellectar Biosciences and...
Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Cellectar Biosciences Inc (CLRB) showcases promising clinical progress and strategic financing, despite ongoing financial hurdles.